Global Roundup: Hansa, OSE Nab New Funding, F-Star Links with Takeda

Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.

Related Keywords

United Kingdom ,Portugal ,Czech Republic ,Germany ,Hungary ,Netherlands ,Israel ,Croatia ,Slovenia ,Italy ,Sweden ,Bulgaria ,Cambridge ,Cambridgeshire ,Poland ,Spain ,France ,Greece ,Romania ,Czechia ,Israeli ,Hansa Biopharma ,Cardinor Secretoneurin ,Donato Spota ,Development Agreement ,Us National Cancer Institute ,Medigus Ltd ,University Of Oxford ,Oxford Science Enterprises ,Drug Administration ,Polyrizon Ltd ,Adani Group ,Nurexone Biologic Inc ,European Medicines Agency ,Cardior Pharmaceuticals ,Tilray Brands Inc ,Novaquest Capital ,Financial Officer Donato Spota ,Biologics License Application ,Cambridge Science ,Star Therapeutics ,F Star Therapeutics ,Sight Robotics ,Israel Based Forsight Robotics ,Eclipse Ventures ,Ribbon Biolabs ,Canada Based Xortx Therapeutics ,Tilray Medical ,Cooperative Research ,Cancer Institute ,Polar Express ,